Theravance Biopharma/TBPH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.

Ticker

TBPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rick Winningham

Employees

99

Headquarters

George town, Cayman Islands

TBPH Metrics

BasicAdvanced
$419M
Market cap
-
P/E ratio
-$0.86
EPS
0.24
Beta
-
Dividend rate
$419M
0.23816
$11.71
$8.13
400K
5.738
-9.84%
-15.56%
-10.39%
6.815
2.043
2.046
26.65%
19.82%
-7.20%

What the Analysts think about TBPH

Analyst Ratings

Majority rating from 5 analysts.
Buy

TBPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-80.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$15M
-17.14%
Net income
-$12M
36.47%
Profit margin
-80.00%
64.71%

TBPH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.51%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.28
-$0.17
-$0.17
-$0.24
-
Expected
-$0.21
-$0.21
-$0.15
-$0.25
-$0.21
Surprise
33.33%
-18.92%
14.35%
-5.51%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Theravance Biopharma stock?

Theravance Biopharma (TBPH) has a market cap of $419M as of June 14, 2024.

What is the P/E ratio for Theravance Biopharma stock?

The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 0 as of June 14, 2024.

Does Theravance Biopharma stock pay dividends?

No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of June 14, 2024.

When is the next Theravance Biopharma dividend payment date?

Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Theravance Biopharma?

Theravance Biopharma (TBPH) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Theravance Biopharma stock price target?

The target price for Theravance Biopharma (TBPH) stock is $15.4, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Theravance Biopharma stock

Buy or sell Theravance Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing